Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography

1997 ◽  
Vol 24 (4) ◽  
pp. 415-421 ◽  
Author(s):  
Klaus Tatsch ◽  
Johannes Schwarz ◽  
P. David Mozley ◽  
Rainer Linke ◽  
Oliver Pogarell ◽  
...  
2000 ◽  
Vol 12 (1-2) ◽  
pp. 11-27 ◽  
Author(s):  
Paul D. Acton ◽  
P. David Mozley

Parkinsonian symptoms are associated with a number of neurodegenerative disorders, such as Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Pathological evidence has shown clearly that these disorders are associated with a loss of neurons, particularly in the nigrostriatal dopaminergic pathway. Positron emission tomography (PET) and single photon emission tomography (SPECT) now are able to visualise and quantify changes in cerebral blood flow, glucose metabolism, and dopaminergic function produced by parkinsonian disorders. Both PET and SPECT have become important tools in the differential diagnosis of these diseases, and may have sufficient sensitivity to detect neuronal changes before the onset of clinical symptoms. Imaging is now being utilised to elucidate the genetic contribution to Parkinson’s disease, and in longitudinal studies to assess the efficacy and mode of action of neuroprotective drug and surgical treatments. This review summarises recent applications of SPECT imaging in the study of parkinsonian disorders, with particular reference to the increasing role it is playing in the understanding, diagnosis and management of these diseases.


1995 ◽  
Vol 22 (1) ◽  
pp. 4-11 ◽  
Author(s):  
B. Ellen Scanley ◽  
Mohammed S. Al-Tikriti ◽  
Mitchell S. Gandelman ◽  
Marc Laruelle ◽  
Yolanda Zea-Ponce ◽  
...  

2005 ◽  
Vol 38 (4) ◽  
pp. 323-329 ◽  
Author(s):  
Antonio Maria Ferro ◽  
Andrea Brugnolo ◽  
Caterina De Leo ◽  
Barbara Dessi ◽  
Nicola Girtler ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document